Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of Vascular Smooth Muscle Cells

被引:40
作者
Chieng-Yane, Pauline [2 ]
Bocquet, Arnaud [1 ]
Letienne, Robert [1 ]
Bourbon, Thierry [1 ]
Sablayrolles, Sylvie [1 ]
Perez, Michel [1 ]
Hatem, Stephane Nicolas [2 ]
Lompre, Anne-Marie [2 ]
Le Grand, Bruno [1 ]
David-Dufilho, Monique [2 ]
机构
[1] Ctr Rech Pierre Fabre, F-81106 Castres, France
[2] Univ Paris 06, Unite Format & Rech Pitie Salpetriere, UMR G56, INSERM, Paris, France
关键词
EXTRACORPOREAL ARTERIOVENOUS SHUNT; PAR1; ANTAGONIST; ANTITHROMBOTIC ACTIVITY; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; THROMBIN; RAT; INFLAMMATION; PREVENTION; PHYSIOLOGY;
D O I
10.1124/jpet.110.175182
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Wound healing after angioplasty or stenting is associated with increased production of thrombin and the activation of protease-activated receptor 1 (PAR1). The aim of the present study was to examine the effects of a new selective PAR1 antagonist, 2-[5-oxo-5-(4-pyridin-2-ylpiperazin-1-yl)-penta-1,3- dienyl]-benzonitrile (F 16618), in restenosis and vascular smooth muscle cell (SMC) proliferation and migration using both in vivo and in vitro approaches. Daily oral administration of F 16618 inhibited the restenosis induced by balloon angioplasty on rat carotid artery in a dose-dependent manner. Furthermore, single intravenous administration of F 16618 during the angioplasty procedure was sufficient to protect the carotid artery against restenosis. In vitro, F 16618 inhibited the growth of human aortic SMCs in a concentration-dependent manner with maximal effects at 10 mu M. At that concentration, F 16618 also prevented thrombin-mediated SMC migration. In vivo, oral and intravenous F 16618 treatments reduced by 30 and 50% the expression of the inflammatory cytokine tumor necrosis factor alpha (TNF alpha) 24 h after angioplasty. However, only acute intravenous administration prevented the induction of matrix metalloproteinase 7 expression. In contrast, F 16618 treatments had no effect on early SMC de-differentiation and transcription of monocyte chemoattractant protein-1 and interleukin-6 and late re-endothelialization of injured arteries. Furthermore, F 16618 compensated for the carotid endothelium loss by inhibiting PAR1-mediated contraction. Altogether, these data demonstrate that PAR1 antagonists such as F 16618 are a highly effective treatment of restenosis after vascular injury, by inhibition of TNF alpha, matrix metalloproteinase 7, and SMC migration and proliferation in addition to an antithrombotic effect.
引用
收藏
页码:643 / 651
页数:9
相关论文
共 39 条
  • [1] Andrade-Gordon P, 2001, J PHARMACOL EXP THER, V298, P34
  • [2] Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction
    Bocquet, Arnaud
    Letienne, Robert
    Sablayrolles, Sylvie
    De Vries, Luc
    Perez, Michel
    Le Grand, Bruno
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 611 (1-3) : 60 - 63
  • [3] Factor Xa: at the crossroads between coagulation and signaling in physiology and disease
    Borensztajn, Keren
    Peppelenbosch, Maikel P.
    Spek, C. Arnold
    [J]. TRENDS IN MOLECULAR MEDICINE, 2008, 14 (10) : 429 - 440
  • [4] Brandes RP, 2001, THROMB HAEMOSTASIS, V85, P1104
  • [5] The nuclear factor-κB-interleukin-6 signalling pathway mediating vascular inflammation
    Brasier, Allan R.
    [J]. CARDIOVASCULAR RESEARCH, 2010, 86 (02) : 211 - 218
  • [6] Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty
    Burchenal, JEB
    Marks, DS
    Mann, JT
    Schweiger, MJ
    Rothman, MT
    Ganz, P
    Adelman, B
    Bittl, JA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (04) : 511 - +
  • [7] Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
    Camerer, E
    Huang, W
    Coughlin, SR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5255 - 5260
  • [8] Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty
    Cipollone, F
    Marini, M
    Fazia, M
    Pini, B
    Iezzi, A
    Reale, M
    Paloscia, L
    Materazzo, G
    D'Annunzio, E
    Conti, P
    Chiarelli, F
    Cuccurullo, F
    Mezzetti, A
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) : 327 - 334
  • [9] Thrombin signalling and protease-activated receptors
    Coughlin, SR
    [J]. NATURE, 2000, 407 (6801) : 258 - 264
  • [10] Proteinase-activated receptors:: novel mechanisms of signaling by serine proteases
    Déry, O
    Corvera, CU
    Steinhoff, M
    Bunnett, NW
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1998, 274 (06): : C1429 - C1452